Access the Full Survey Report
Genezen conducted a survey among top executives at biopharmaceutical companies and payor organizations to uncover how their strategies for negotiating reimbursement are shaping the development and commercialization of cell and gene therapies.
Key Insights Include:
- 70% of respondents say CGT reimbursement is more complex than traditional therapies.
- 52% of companies have adjusted their development strategies due to reimbursement challenges.
- 42% of companies found that reimbursement negotiations didn’t align with investor expectations.
Access the full report to gain insights on:
- Reimbursement models that are reshaping the CGT market.
- How companies are adapting development plans for success.
- Investment sentiment and the factors influencing investor confidence.
